Lu-177 vs Ac-225 therapy for prostate cancer.

The science: beta vs alpha

Lu-177 and Ac-225 share a delivery vehicle. Both isotopes are bound to the same small molecule — PSMA-617 — that locks onto Prostate-Specific Membrane Antigen, a protein expressed in very high concentrations on prostate cancer cells and only sparingly on healthy tissue. The PSMA ligand finds the cancer cell. The isotope is the warhead.

What differs is the warhead. Lu-177 emits beta particles — high-energy electrons that travel an average of 2 millimetres through tissue, depositing energy in a relatively long path with moderate density. This is why beta therapy works on tumours that have a substantial amount of cancer in a region — a single Lu-177 atom can damage cells slightly distant from where it lands, which is helpful when not every cell in the tumour expresses PSMA at the same level.

Ac-225 emits alpha particles — far heavier, far more massive, far slower. Alpha particles travel less than 100 micrometres in tissue. That is roughly the diameter of a single cell. Within that tiny range, an alpha particle deposits 200 to 500 times more energy per micrometre than a beta particle. The result is a near-lethal dose to the cell that is hit, with almost no spillover to neighbouring cells. The lethality per particle is extreme. The collateral damage is minimal.

Two practical implications follow from this physics. First, Ac-225 is more effective on small-volume disease where every targeted cell needs to be killed cleanly — including micrometastases that beta range overshoots. Second, Lu-177 has slightly more forgiveness in heterogeneously-expressing tumours, because its longer range covers the cells the ligand may not have reached directly. Neither isotope is universally superior. The correct one depends on the disease in front of you.

The evidence base — what we actually know

The evidence pyramid behind these two therapies is not yet symmetrical. Lu-177 PSMA-617 is supported by the strongest possible kind of clinical evidence: a multicentre, international, phase III randomised controlled trial. The VISION trial¹, published in the New England Journal of Medicine in 2021, randomised 831 patients with metastatic castration-resistant prostate cancer (mCRPC) to either Lu-177 PSMA-617 plus standard of care or standard of care alone. The therapy arm showed a statistically significant improvement in overall survival (15.3 months vs 11.3 months) and radiographic progression-free survival (8.7 months vs 3.4 months). On the strength of those results, the U.S. Food and Drug Administration approved Lu-177 PSMA-617 in March 2022 under the brand name Pluvicto.

Ac-225 PSMA-617 sits earlier on the evidence curve. There is no completed phase III trial yet — the AcTION and AlphaBet trials, both currently enrolling, will fill that gap over the next 24 months. What exists today are an expanding set of investigator-initiated case series, single-centre experiences, and one large 2024 systematic review² (PMC11905128) that aggregated outcomes from over 1,500 patients across multiple international centres. Our team's published Indian case series³ contributed to that body of evidence. The pooled finding, in patients refractory to Lu-177, is that approximately 60-65% achieve a meaningful PSA decline on Ac-225, with median overall survival in the range of 9-15 months from the start of alpha therapy.

The two facts to hold in tension here are: Lu-177's evidence is one tier higher; and Ac-225 has been studied largely in the harder population — patients whose disease has already failed Lu-177 — which understates its true biological power. A trial in untreated, alpha-naive patients would likely show different numbers. That is what AcTION will test.

Side effects, and what they feel like

The side-effect profiles of the two therapies are similar in shape and different in degree. Both can cause fatigue, mild nausea, and a transient drop in blood counts. Both protect the kidneys aggressively — Lu-177 with hydration alone in most patients, Ac-225 sometimes with additional renal protection on a case-by-case basis. The single most discussed difference is what happens to the salivary glands.

The salivary glands express PSMA at low but detectable levels. Lu-177's longer beta range means a fraction of the dose intended for the tumour also reaches them — but the energy deposition per cell is moderate, and most patients experience only mild xerostomia (dry mouth) that is reversible over weeks. Ac-225's lethality per cell is much higher, and even though the ligand binds to the salivary glands at the same low level, the cellular kill there is more pronounced. Xerostomia is the dose-limiting toxicity of Ac-225, and the toxicity that determines whether a patient can complete a full course.

Several mitigation strategies — cold packs, salivary gland salivary stimulation, dose fractionation, and emerging work on intra-arterial administration — have meaningfully reduced xerostomia rates over the last three years. Our group's 2024 paper in Theranostics⁴ on dose-fractionated Ac-225-PSMA-617 demonstrated that fractionating the dose across the cycle preserves efficacy while substantially reducing salivary toxicity. This is one of the active research frontiers, and the picture is improving fast.

The cost conversation — India vs the West

Cost is the part of this conversation that often goes unspoken in clinical articles. We will not avoid it, because it is what determines what is actually possible for most families.

Two qualifiers belong here. First: the figures above are indicative — the precise cost in any given case depends on the dose calculated from PSMA PET imaging, the patient's renal function, and whether additional supportive measures are required. Second: a clinical decision should never be a financial decision in disguise. If Ac-225 is the right call biologically, it is the right call. The cost gap matters because it changes who can access the right call — not because it changes what the right call is.

The reason an Indian centre can deliver the same molecule, the same protocol, the same isotope, at roughly one-fifth of the US figure has to do with healthcare cost structures, not with quality. The Lu-177 used at FMRI is the same Lu-177 used in Heidelberg or New York. The PSMA-617 ligand is sourced from the same approved vendors. The protocols follow the same published guidelines. The difference is in the system around the molecule, not in the molecule itself.

How we sequence them — the clinical logic

For most patients with mCRPC who are PSMA-PET positive and have exhausted hormone-based options, the standard sequence at our centre is Lu-177 first, then re-imaging, then a structured decision about whether to continue Lu-177, switch to Ac-225, or change strategy entirely. The triggers for moving from Lu to Ac are reasonably well-defined now. They are:

• Rising PSA after at least four Lu-177 cycles, with imaging confirmation that the rise reflects true progression rather than a tumour-flare phenomenon.
• A PSMA PET-CT that shows new lesions appearing during Lu-177 therapy — particularly small-volume bone or marrow disease, where alpha's short range is mechanistically advantageous.
• Patients with extremely high tumour volume at baseline, where the calculation may favour alpha's higher per-cell cell kill from the outset. This decision is individual and made jointly with the medical oncology team.
• Patients with disease in sanctuary sites — diffuse bone marrow involvement or visceral metastases — where beta range becomes a liability rather than an advantage.

We do not switch to Ac-225 because Lu-177 is unavailable, or because the patient has heard about alpha therapy and prefers it. The decision must be biology-driven, not preference-driven. Patients who escalate to Ac-225 for the right reasons — meaning the disease has demonstrably moved on from beta therapy — are the patients who tend to respond. Patients who escalate without that biological rationale tend to face higher toxicity for limited additional benefit.

The Indian context

India occupies a distinctive position in the global radioligand therapy landscape. We have access to both Lu-177 and Ac-225 isotopes through the Bhabha Atomic Research Centre and through international partnerships, the regulatory pathway (TPG 2020) supports therapeutic use, and centres like FMRI have built more than a decade of clinical experience in PSMA imaging and therapy. The cost structure makes treatment accessible to international patients from regions where Ac-225 is not available at all — including parts of Europe, Australia, and Southeast Asia — and where Pluvicto, even when available, is gated by insurance approval timelines that can stretch to several months.

What is not yet established here is the layer of E-E-A-T signalling — the publications page properly catalogued, the physician profile pages with full structured data, the FAQ hub built for AI search citation. The clinical authority is genuine. The discoverability of that authority is what the next eighteen months of work is about. This article is part of that work.

A closing thought

If you have read this far, you are likely either a patient or family member working through a serious diagnosis, or a clinician trying to make a difficult sequencing decision. To both: the right therapy is rarely the most aggressive available therapy, and rarely the most newly approved one. It is the therapy whose mechanism matches the biology of the disease as it stands today, and whose cost and toxicity profile fit what the patient and family can absorb. For most prostate cancer patients reaching radioligand therapy in 2026, that means Lu-177 first, performed carefully, with the option to escalate to Ac-225 held in reserve for the moment when — and if — the biology shifts.

The next two years will give us better data. AcTION and AlphaBet will likely tighten the indications. Tb-161, an emerging third option in this category, will probably enter selected pathways. The framework above will be updated as those data mature. For now, this is how we think about it, and how we explain it to the people who walk into our clinic asking the same questions you may have when reading this.